JP5774309B2 - 癌マーカーおよび治療ターゲット - Google Patents

癌マーカーおよび治療ターゲット Download PDF

Info

Publication number
JP5774309B2
JP5774309B2 JP2010525420A JP2010525420A JP5774309B2 JP 5774309 B2 JP5774309 B2 JP 5774309B2 JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010525420 A JP2010525420 A JP 2010525420A JP 5774309 B2 JP5774309 B2 JP 5774309B2
Authority
JP
Japan
Prior art keywords
ccr4
tumor
cancer
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010525420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539508A5 (enExample
JP2010539508A (ja
Inventor
バルクウィル フランシス
バルクウィル フランシス
スレテナー ヴァイオレット
スレテナー ヴァイオレット
ウィルソン ジュリア
ウィルソン ジュリア
ワング ヤオヘ
ワング ヤオヘ
シチオッパ ティジアナ
シチオッパ ティジアナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5774309(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2010539508A publication Critical patent/JP2010539508A/ja
Publication of JP2010539508A5 publication Critical patent/JP2010539508A5/ja
Application granted granted Critical
Publication of JP5774309B2 publication Critical patent/JP5774309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
JP2010525420A 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット Expired - Fee Related JP5774309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167.0 2007-09-18
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015131752A Division JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Publications (3)

Publication Number Publication Date
JP2010539508A JP2010539508A (ja) 2010-12-16
JP2010539508A5 JP2010539508A5 (enExample) 2012-10-04
JP5774309B2 true JP5774309B2 (ja) 2015-09-09

Family

ID=38670078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525420A Expired - Fee Related JP5774309B2 (ja) 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2535716B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2533047T3 (enExample)
ES (3) ES2443541T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2535716T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
EP2580348B1 (en) * 2010-06-14 2018-04-25 Qiagen GmbH Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
PL3065774T3 (pl) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
WO2016050904A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
AU2016248222A1 (en) * 2015-04-17 2017-11-09 Eisai, Inc. Methods for treating lung cancer
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
JP7177445B2 (ja) * 2017-05-19 2022-11-24 真吾 前田 Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法
ES3064498T3 (enExample) 2018-08-29 2026-04-27 Chemocentryx Inc
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
WO1994021814A1 (en) * 1993-03-19 1994-09-29 The Johns Hopkins University Antibodies and assays for determining mutations in the apc gene
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
AU2002223619B2 (en) 2000-10-18 2006-08-24 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
MXPA03007681A (es) * 2001-02-28 2004-11-12 Protein Design Labs Inc Receptores para quimiocinas y enfermedades.
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
CA2456928A1 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1984501B1 (en) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
ES2612690T3 (es) 2017-05-18
EP2176664A2 (en) 2010-04-21
RU2010123921A (ru) 2011-12-20
GB0718167D0 (en) 2007-10-31
WO2009037454A2 (en) 2009-03-26
DK2535716T3 (en) 2017-02-13
EP2533047B1 (en) 2016-05-11
DK2176664T3 (da) 2014-01-20
US20100278844A1 (en) 2010-11-04
US9134293B2 (en) 2015-09-15
US10261099B2 (en) 2019-04-16
RU2014128513A (ru) 2016-02-10
EP2176664B1 (en) 2013-11-06
ES2588507T3 (es) 2016-11-03
CA2699702C (en) 2018-03-06
PL2533047T3 (pl) 2016-11-30
EP2535716A2 (en) 2012-12-19
WO2009037454A3 (en) 2009-05-07
AU2008300413A1 (en) 2009-03-26
EP2535716A3 (en) 2013-03-13
JP6234967B2 (ja) 2017-11-22
EP2533047A1 (en) 2012-12-12
JP2015212703A (ja) 2015-11-26
RU2529797C2 (ru) 2014-09-27
JP2010539508A (ja) 2010-12-16
EP2535716B1 (en) 2016-11-02
CA2699702A1 (en) 2009-03-26
PL2176664T3 (pl) 2014-04-30
ES2443541T3 (es) 2014-02-19
US20160223572A1 (en) 2016-08-04
PL2535716T3 (pl) 2017-06-30
AU2008300413B2 (en) 2014-09-11
DK2533047T3 (en) 2016-08-22

Similar Documents

Publication Publication Date Title
JP6234967B2 (ja) 癌マーカーおよび治療ターゲット
Ni et al. Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients
Ottaiano et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
Kislin et al. NHERF-1: modulator of glioblastoma cell migration and invasion
JP2013520958A (ja) 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
Wang et al. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer
CN116137862A (zh) 三级淋巴结构在预后疾病进展和治疗癌症中的应用
EP2831593B1 (en) S100a8/a9 as a diagnostic marker and a therapeutic target
Cheng et al. Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients
AU2013203369B2 (en) Cancer marker and therapeutic target
JP2015509186A (ja) 乳癌の検出及び処置
Chutipongpisit et al. Immunohistochemical and immunofluorescence expression profile of lymphatic endothelial cell markers in oral cancer
JP7012363B2 (ja) がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
WO2012103424A2 (en) Diagnostic and prognostic markers for metastasis
Maeda et al. Roles of C-reactive protein and LOX-1 on cancer and myeloid-derived suppressor cells in the progression of uterine cervical cancer
Qiao et al. Loss of protein tyrosine phosphatase receptor J expression predicts an aggressive clinical course in patients with esophageal squamous cell carcinoma
JP7042753B2 (ja) 免疫チェックポイント阻害剤の投与対象となる個体の選択方法
JP2008035836A (ja) 腫瘍マーカー
Jia et al. CYR61 confers the sensitivity to aromatase inhibitor Letrozole in ER positive breast carcinoma
JP2024522257A (ja) 癌の治療のための診断方法および組成物
JPWO2017022634A1 (ja) グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物
Pagano The potential role of CXCR4 and SDF-1 as indicators of tumor aggressiviness in patients with conventional papillary thyroid carcinoma
Corvigno Tumour microenvironment in serous ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150701

R150 Certificate of patent or registration of utility model

Ref document number: 5774309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees